{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:02:51Z","timestamp":1761861771339,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Retina.net e.V."},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Das Retina.net ROP-Register erhebt Daten von Kindern, die eine seltene behandlungsbed\u00fcrftige Fr\u00fchgeborenenretinopathie (Retinopathy of Prematurity, ROP) entwickeln. <jats:italic>Ziel<\/jats:italic> dieser Auswertung ist die Untersuchung der Daten zur behandlungsbed\u00fcrftigen ROP, Epidemiologie, Therapie und deren \u00c4nderungen \u00fcber einen Zeitraum von 15\u00a0Jahren an der Medizinischen Hochschule Hannover.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Analyse der Daten der therapiebed\u00fcrftigen F\u00e4lle der ROP eines Zentrums f\u00fcr die Geburtsjahre 2001 bis 2016 (Therapie in 2002 bis 2017) als Gesamtzeitraum und in 5\u00a0Abschnitten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es wurden 65\u00a0Kinder behandelt (23\u00a0weiblich), davon wurden\u00a011 (16,9\u202f%) extern auf ROP gescreent und zur ROP-Behandlung zugewiesen. F\u00fcr den Zeitraum 2006 bis 2016 lag die Inzidenz der behandlungsbed\u00fcrftigen ROP unter den gescreenten Kindern bei 4,1\u202f%. Das mittlere Gestationsalter betrug 25,7\u00a0Schwangerschaftswochen (SSW) (Standardabweichung [SA]\u202f=\u20091,8), das Geburtsgewicht 763\u202fg (SA\u202f=\u2009235), das postmenstruelle Alter bei Behandlung 38,2\u00a0Wochen (SA\u202f=\u20093,2), das postnatale Alter 12,4\u00a0Wochen (SA\u202f=\u20093,2). \u00dcber die Zeit zeigte sich kein signifikanter Unterschied der demografischen Parameter. Am h\u00e4ufigsten (57\u00a0Augen bei 31\u00a0Kindern) wurde eine Zone\u00a0II, 3+-Erkrankung behandelt; 58\u00a0Kinder erhielten eine Laserkoagulation (<jats:italic>N<\/jats:italic>\u202f=\u2009114 Augen), 7\u00a0Kinder bilateral eine Anti-VEGF-Therapie (Bevacizumab) (<jats:italic>N<\/jats:italic>\u202f=\u200914\u00a0Augen), welche ab 2014 eingesetzt wurde. Eine Wiederbehandlung bei Wiederaufflammen der behandlungsbed\u00fcrftigen ROP war in einem Fall nach initialer Laserbehandlung notwendig. Kinder mit behandlungsbed\u00fcrftiger ROP zeigten h\u00e4ufig neonatologische Komorbidit\u00e4ten, in mehr als 90\u202f% Beatmung, bronchopulmonale Dysplasie und erhielten Transfusionen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Dies ist die erste monozentrische Auswertung \u00fcber 15\u00a0Jahre im Rahmen des Retina.net ROP-Registers. Ab 2014 sehen wir einen Wechsel von der Laserkoagulation zur Anti-VEGF-Therapie (Bevacizumab), w\u00e4hrend im betrachteten Kollektiv die demografischen Daten und Behandlungsparameter weitgehend konstant waren.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-021-01528-9","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T20:38:03Z","timestamp":1637613483000},"page":"497-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epidemiologie und Therapie der behandlungsbed\u00fcrftigen Fr\u00fchgeborenenretinopathie. Die Hannoveraner Daten im Retina.net ROP-Register von 2001 bis 2017","Epidemiology and treatment of retinopathy of prematurity. The Hannover data in the Retina.net ROP registry from 2001\u20132017"],"prefix":"10.1007","volume":"119","author":[{"given":"Stella H.","family":"Akman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"B\u00f6hne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Bohnhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Framme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bajor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Hufendiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-2501","authenticated-orcid":false,"given":"Amelie","family":"Pielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Retina.net ROP Register-Studiengruppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella H.","family":"Akman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bajor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Framme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Hufendiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Mies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Pielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Wojtera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Bohnhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"B\u00f6hne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Zirkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"1528_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-020-01170-x","author":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG)","year":"2020","unstructured":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG), Retinologische Gesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA) (2020) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zur Anti-VEGF-Therapie der Fr\u00fchgeborenenretinopathie: Stand: 18.05.2020. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-020-01170-x","journal-title":"Ophthalmologe"},{"key":"1528_CR2","unstructured":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG), Retinologische Gesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA) (2020) Stellungnahme von DOG, RG und BVA zur Anti-VEGF-Therapie der Fr\u00fchgeborenenretinopathie; ROP-Pass-Formular zum Download. https:\/\/www.dog.org\/wp-content\/uploads\/2013\/03\/ROP-Pass_Version-3_4_FORMULAR.pdf. Zugegriffen: 14.\u00a0Okt. 2021"},{"key":"1528_CR3","doi-asserted-by":"publisher","first-page":"F337","DOI":"10.1136\/archdischild-2017-313574","volume":"103","author":"R Gerull","year":"2018","unstructured":"Gerull\u00a0R, Brauer\u00a0V, Bassler\u00a0D et al (2018) Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006\u20132015: a\u00a0population-based analysis. Arch Dis Chil Fetal Neonatal Ed 103:F337\u2013F342. https:\/\/doi.org\/10.1136\/archdischild-2017-313574","journal-title":"Arch Dis Chil. Fetal Neonatal Ed"},{"key":"1528_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/bjophthalmol-2019-314874","volume":"104","author":"G Holmstr\u00f6m","year":"2020","unstructured":"Holmstr\u00f6m\u00a0G, Hellstr\u00f6m\u00a0A, Gr\u00e4nse\u00a0L et al (2020) New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 104:943\u2013949. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314874","journal-title":"Br J Ophthalmol"},{"key":"1528_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307263","author":"G Holmstrom","year":"2016","unstructured":"Holmstrom\u00a0G, Hellstrom\u00a0A, Jakobsson\u00a0P et\u00a0al (2016) Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a\u00a0national quality register. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307263","journal-title":"Br J Ophthalmol"},{"key":"1528_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu\u00a0J, Blair\u00a0MP, Shapiro\u00a0MJ et\u00a0al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol"},{"key":"1528_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen\u00a0PP, Br\u00fcnder\u00a0M\u2011C, Petrak\u00a0M et al (2018) Screening for retinopathy of prematurity: trends over the past 5\u00a0years in two German university hospitals. Ophthalmologe 115:469\u2013475. https:\/\/doi.org\/10.1007\/s00347-018-0675-3","journal-title":"Ophthalmologe"},{"key":"1528_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/archdischild-2020-319767","volume":"106","author":"PP Larsen","year":"2021","unstructured":"Larsen\u00a0PP, M\u00fcller\u00a0A, Lagr\u00e8ze\u00a0WA et\u00a0al (2021) Incidence of retinopathy of prematurity in Germany: evaluation of current screening criteria. Arch Dis Child Fetal Neonatal Ed 106:189\u2013193. https:\/\/doi.org\/10.1136\/archdischild-2020-319767","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1528_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-021-01393-6","author":"JQ Li","year":"2021","unstructured":"Li\u00a0JQ, Kellner\u00a0U, Lorenz\u00a0B et al (2021) Screening for retinopathy of prematurity-the most important changes in the new German guidelines 2020. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-021-01393-6","journal-title":"Ophthalmologe"},{"key":"1528_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00417-009-1077-7","volume":"247","author":"B Lorenz","year":"2009","unstructured":"Lorenz\u00a0B, Spasovska\u00a0K, Elflein\u00a0H, Schneider\u00a0N (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a\u00a0multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251\u20131262. https:\/\/doi.org\/10.1007\/s00417-009-1077-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1528_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-021-01353-0","author":"RF Maier","year":"2021","unstructured":"Maier\u00a0RF, Hummler\u00a0H, Kellner\u00a0U et al (2021) Augen\u00e4rztliche Screening-Untersuchung bei Fr\u00fchgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr.\u00a0024\/010, M\u00e4rz 2020): Gemeinsame Empfehlung von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV., Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI). Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-021-01353-0","journal-title":"Ophthalmologe"},{"key":"1528_CR12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner\u00a0HA, Geloneck\u00a0MM, Chuang\u00a0AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"key":"1528_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner\u00a0HA, Kennedy\u00a0KA, Chuang\u00a0AZ, Group B\u2011RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"1528_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jpeds.2015.10.080","volume":"169","author":"J Spiegler","year":"2016","unstructured":"Spiegler\u00a0J, Preu\u00df\u00a0M, Gebauer\u00a0C et\u00a0al (2016) Does breastmilk influence the development of bronchopulmonary dysplasia? J\u00a0Pediatr 169:76\u201380.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2015.10.080","journal-title":"J Pediatr"},{"key":"1528_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14852","author":"A Stahl","year":"2021","unstructured":"Stahl\u00a0A, Br\u00fcnder\u00a0M, Lagr\u00e8ze\u00a0WA et al (2021) Ranibizumab in retinopathy of prematurity\u2014one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.14852","journal-title":"Acta Ophthalmol"},{"key":"1528_CR16","first-page":"500","volume":"33","author":"A Stahl","year":"2012","unstructured":"Stahl A, Krohne T, Limburg E (2012) Register zur Erfassung behandlungsbed\u00fcrftiger Fr\u00fchgeborenenretinopathie. Z Prakt Augenheilkd 33:500\u2013504","journal-title":"Z Prakt Augenheilkd"},{"key":"1528_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838","author":"A Stahl","year":"2018","unstructured":"Stahl\u00a0A, Krohne\u00a0TU, Eter\u00a0N et\u00a0al (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"1528_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13069","author":"JM Walz","year":"2016","unstructured":"Walz\u00a0JM, Bemme\u00a0S, Pielen\u00a0A et\u00a0al (2016) The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.13069","journal-title":"Acta Ophthalmol"},{"key":"1528_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz\u00a0JM, Bemme\u00a0S, Reichl\u00a0S et al (2018) Treated cases of retinopathy of prematurity in Germany: 5\u2011year data from the Retina.net ROP registry. Ophthalmologe 115:476\u2013488. https:\/\/doi.org\/10.1007\/s00347-018-0701-5","journal-title":"Ophthalmologe"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01528-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-021-01528-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01528-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T10:17:48Z","timestamp":1651832268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-021-01528-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s00347-021-01528-9","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"type":"print","value":"0941-293X"},{"type":"electronic","value":"1433-0423"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"20 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.M.\u00a0Pfeil ist Mitglied der Retinologischen Gesellschaft (RG). A.\u00a0Stahl: <b>Referenten\u2011\/Beratert\u00e4tigkeiten: <\/b>Novartis, Bayer, Allergan, Roche, <b>Studienunterst\u00fctzung und Drittmittel:<\/b> Novartis, Bayer, <b>Mitgliedschaften in Fachgesellschaften:<\/b> DOG, RG (Vorstandsmitglied), Retina.net e.\u202fV. (Sprecher des Vorstands). C.\u00a0Framme: <b>Referenten\u2011\/Beratert\u00e4tigkeiten: <\/b>Novartis, Bayer, Allergan, MedUpdate, <b>Studienunterst\u00fctzung und Drittmittel: <\/b>Roche, Novartis, Bayer, <b>Mitgliedschaften in Fachgesellschaften: <\/b>DOG, BVA, RG, Retina.net, VNDA. D.\u00a0Brockmann: <b>Studienunterst\u00fctzung und Drittmittel: <\/b>Recordati Rare diseases. A.\u00a0Bajor<b>: Referenten\u2011\/Beratert\u00e4tigkeiten: <\/b>GSK, <b>Studienunterst\u00fctzung und Drittmittel: <\/b>Novartis, Bayer, Allergan, Roche, Chengdu Kanghong, B\u00f6hringer Ingelheim, Sanofi Aventis, Recordati Rare Diseases, ICON, TFS, iveriqbio, <b>Mitgliedschaften in Fachgesellschaften: <\/b>DOG. C.\u00a0Jacobsen und K.\u00a0Hufendiek: <b>Mitgliedschaften in Fachgesellschaften: <\/b>DOG. A.\u00a0Pielen<b>: Referenten\u2011\/Beratert\u00e4tigkeiten: <\/b>Novartis, Bayer, Allergan, Roche, Sanofi Aventis, <b>Studienunterst\u00fctzung und Drittmittel: <\/b>Novartis , Bayer, Allergan, Roche, Chengdu Kanghong, B\u00f6hringer Ingelheim, Sanofi Aventis, Recordati Rare Diseases, ICON, TFS, iveriqbio, <b>Mitgliedschaften in Fachgesellschaften:<\/b> DOG, BVA, RG, Retina.net e.\u202fV., VNDA. S.H.\u00a0Akman, S.\u00a0Ehlers, C.\u00a0B\u00f6hne und B.\u00a0Bohnhorst geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen wurden mit Zustimmung der zust\u00e4ndigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}